DVA|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.58 | - | - |
| Q2'26 | $3.92 | $4.02 | +2.5% |
| Q1'26 | $2.33 | $2.87 | +23.2% |
| Q3'25 | $3.17 | $2.51 | -20.9% |
| Q2'25 | $2.75 | $2.95 | +7.3% |
| Q1'25 | $2.02 | $2.00 | -1.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $3.5B | - | - |
| Q2'26 | $3.5B | $3.6B | +0.6% |
| Q1'26 | $3.4B | $3.4B | +1.8% |
| Q3'25 | - | $3.4B | - |
| Q2'25 | - | $3.4B | - |
| Q1'25 | - | $3.2B | - |
Market Data
DVA Stock Snapshot
DVA is currently trading at $172.63, giving DaVita Inc. a market cap of 11.56B and a P/E ratio of 13.6. Today's range spans $175.29–$179.34, with shares opening at $175.60 and moving down $1.16 (0.7%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 67/100.
Over the past year DVA has traded between $101.00 and $247.49 - the current price is +70.9% off the 52-week low and -30.2% from the high.
Earnings estimate risk is at the forefront for DaVita Inc. (DVA) - a large-cap Healthcare name (11.56B market cap) showing a SELL (27/100) alongside bullish sentiment (67/100) often flags a period where consensus estimates are still catching down to what the market is already pricing in. Price: $172.63 (in the middle of its 52-week range in $101.00–$247.49). (P/E: 13.6) Active managers who track the technical-fundamental gap tend to position ahead of the revision, not after it.
When a large-cap Healthcare name with 11.56B in capitalization prints a SELL signal (27/100) alongside bullish news sentiment (67/100), the risk isn't just price depreciation, it's the loss of institutional sponsorship that makes recovery harder. At $172.63 (in the middle of its 52-week range in the $101.00–$247.49 range), the structural support levels are where that sponsorship question gets answered.
Company Insights: DaVita Inc. (DVA)
DaVita’s market cap of $11.49 B underscores its status as the largest dialysis provider in the U.S., yet the company continues to navigate reimbursement volatility amid shifting CMS policies. The firm’s core revenue stream, outpatient hemodialysis, remains largely contract‑based, providing a predictable cash flow cushion against rate fluctuations. Recent upgrades by TD Cowen to Buy and a price target of $220 signal confidence that Medicare Advantage contracts will offset any short‑term margin pressure. The company’s integrated laboratory and home‑dialysis services diversify income and support patient retention. DaVita’s strategic focus on middle‑molecule dialysis positions it to capture higher reimbursement rates as CMS expands coverage.
The stock’s 1‑year return of 56.9% outpaces the broader healthcare sector, reflecting disciplined earnings growth and a favorable valuation multiple. Six‑month gains of 22% demonstrate resilience during a period of rising sentiment, while the 3‑month decline of 6.2% highlights short‑term volatility. DaVita’s earnings beat in four of the last six quarters indicates management’s ability to navigate cost pressures. The company’s EPS grew 40% from Q1 to Q2 2026, a sharp acceleration compared to the 12% increase seen in the previous year. This earnings momentum is supported by a growing patient volume base and expanding service mix.
DaVita trades at a forward PE of 13.56, well below the peer average of 53.0 across AbbVie, Abbott Laboratories and others, offering a valuation discount in a mature sector. The company’s lower multiple reflects its focused business model and lower growth prospects relative to diversified peers, yet it provides a margin of safety for value‑oriented investors. The disparity also signals that the market may be underpricing DaVita’s stable cash flows and strong reimbursement contracts. Investors can leverage this discount while monitoring the company’s ability to sustain earnings growth through operational efficiencies. The peer comparison underscores the potential upside if DaVita capitalizes on favorable reimbursement changes.
Sentiment has risen 22 points over the past 14 days, reaching a score of 70, and recent analyst coverage has highlighted the stock’s undervaluation relative to earnings potential. The 52‑week low of $101 remains a critical support level, while the high of $247.49 represents a ceiling that has not yet been breached. Positive news from TD Cowen and BofA, coupled with a 56.9% year‑to‑date return, suggests that the market may be re‑pricing the company’s growth prospects. However, the company’s exposure to reimbursement policy changes and the cyclical nature of healthcare demand remain key risks. Monitoring CMS reimbursement announcements and home‑dialysis enrollment metrics will provide early signals of valuation shifts.
Reimbursement Resilience
DaVita has secured long‑term contracts with Medicare Advantage plans, providing predictable cash flow amid policy shifts.
The company’s focus on middle‑molecule dialysis has opened higher reimbursement corridors, offsetting pressure on standard hemodialysis rates.
Recent upgrades by TD Cowen reflect confidence that upcoming CMS rate adjustments will lift margins despite inflationary headwinds.
Volume Expansion
Q2 2026 revenue rose 3.8% YoY to $3.55 B, driven by a 2.3% increase in patient visits across its 1,300 centers.
DaVita’s home‑based dialysis program has expanded by 18% in the last 12 months, capturing a growing segment of outpatient care.
The company’s integrated laboratory services generate ancillary revenue, diversifying its income beyond core hemodialysis.
Peer Discount
At a forward PE of 13.6, DaVita trades well below the peer average of 53.0, signaling a valuation discount amid sector consolidation.
Competitors such as AbbVie and Abbott Laboratories command higher multiples due to diversified product lines and stronger growth prospects.
This disparity offers a margin of safety for investors looking for exposure to a mature healthcare niche at attractive pricing.
Capital Allocation
DaVita has maintained a disciplined capital return program, returning $1.2 B to shareholders through dividends and buybacks in 2025.
The company’s debt profile remains modest, with a debt‑to‑equity ratio of 0.4, allowing flexibility to fund expansion.
Recent guidance indicates continued investment in technology upgrades for dialysis machines, supporting long‑term operational efficiency.
Market Sentiment
The stock’s sentiment score of 70, coupled with a 22‑point rise over 14 days, suggests growing investor confidence.
Positive coverage from TD Cowen and BofA has reinforced the narrative of undervaluation relative to earnings potential.
However, the 52‑week low of $101 remains a critical support level that could trigger a reassessment if breached.
Regulatory Landscape
DaVita’s operations are heavily regulated by CMS, requiring compliance with stringent quality metrics that can impact reimbursement.
The recent CMS proposal to increase reimbursement for middle‑molecule dialysis could boost margins by up to 4% annually.
The company’s proactive engagement with policy makers positions it to capitalize on favorable regulatory changes before competitors.
Positioning DVA
DaVita’s current price of $184 sits 72.5% above the 52‑week low, positioning the stock within a healthy upside corridor yet below the $247.49 high. The TD Cowen upgrade to Buy and a price target of $220 suggest a 20% upside from the current level, while BofA’s $170 target underscores potential downside if reimbursement pressures intensify. Add exposure when the share price approaches the 52‑week low and sentiment remains bullish, as mean‑reversion dynamics often play out in the dialysis sector. Reduce weight when the price nears the $220 target or the 52‑week high, indicating a potential valuation peak. Monitor CMS reimbursement announcements and home‑dialysis enrollment metrics as catalysts that could shift the valuation range. Position sizing should account for the company’s low beta and the broader healthcare sector’s cyclical nature.
Risk Factors
DaVita’s risk landscape is dominated by reimbursement policy swings, patient volume dynamics, capital intensity, regulatory oversight, and short‑term market sentiment. The company’s financial health hinges on Medicare and Medicaid pricing decisions, while its expansion strategy relies on disciplined capital deployment. Regulatory changes can impose costly compliance mandates, and any sustained patient decline would erode per‑center throughput. Market volatility can amplify earnings surprises, creating a fragile short‑term outlook.
- Short-Term Volatility Post-Beat
The sharp 1‑month decline of 19.8% following the Q2 2026 earnings beat suggests heightened market sensitivity to earnings surprises. This volatility indicates that the market may have overreacted to the positive earnings, creating a temporary price distortion. The price swing could erode shareholder value and dampen future capital‑raising efforts. Leading signals include the day‑after‑earnings trading volume, analyst revisions, and the spread between the 30‑day moving average and the current price. The effect is most pronounced in the immediate trading week after earnings, with a potential re‑acceleration if subsequent guidance falls short.
Key Metrics for DVA
DaVita’s valuation hinges on its ability to grow patient volume while navigating reimbursement volatility and maintaining margin resilience. Multi‑year themes, steady volume expansion, favorable Medicare/Medicaid policy, and a shift toward home dialysis, drive the company’s revenue engine and cost structure. These dynamics shape the earnings narrative and determine how the market prices DVA’s future cash flows.
Price Recovery Trajectory: Short‑term price swings often mask longer‑term value. DVA’s share price fell 19.8% over the last month and 6.2% over the last three months, yet it has rebounded 22% over six months and surged 56.9% over the past year. The recent decline reflects broader market volatility rather than a fundamental shift in DVA’s business model. A sustained 1‑year gain of nearly 60% indicates that the market is pricing in the company’s long‑term growth prospects, especially its volume expansion and margin resilience. Investors will watch the next quarterly performance for any signs of a short‑term reversal, but the current trajectory suggests a bullish stance for the near future.
What Moves DVA Stock?
DaVita’s share price is most acutely driven by Medicare reimbursement policy, which dictates the bulk of its revenue and margin profile. The company’s 56.9% return over the past year reflects how well it has capitalized on favorable payment adjustments and volume growth. Sentiment has been rising, with a 70 score, and analysts are increasingly bullish, as seen in TD Cowen’s buy upgrade. The remaining drivers, patient volume, home dialysis expansion, lab services, and capital allocation, add nuance but rarely eclipse the reimbursement narrative.
Medicare Reimbursement Policy
When Medicare adjusts the dialysis reimbursement rate, DVA's earnings and valuation shift sharply. A 5% increase can lift revenue by roughly 3% and EPS by 4%, as seen in 2022. The market reacts within days, often re‑pricing the share by 8–12%. This sensitivity makes reimbursement policy the most powerful driver of DVA's share price.
Historically, a 5% rate hike in 2022 lifted revenue by 3% and EPS by 4%. In 2021, a 3% reduction in rates forced a 2% decline in revenue and a 1.5% EPS dip. These swings underscore the policy's volatility. Analysts frequently model multiple scenarios to capture this risk.
The policy is set quarterly; monitoring CMS announcements and the upcoming Medicare payment reform is key. A positive change in the ESRD payment formula can trigger a near‑term rally. Conversely, a cap on reimbursement can compress margins and trigger a sell‑off. Investors should watch the CMS ESRD payment update and the Medicare Payment Advisory Group (MPAG) releases.
Patient Volume Growth
Over the last five years, DVA has increased patient volume by 2% annually, contributing to a 6% revenue rise. The company’s network of 1,300 dialysis centers serves about 300,000 patients. Volume growth is a core metric in earnings forecasts, often driving the consensus EPS upward. Sustained volume expansion has historically translated into share price appreciation.
Higher volume expands the fee‑for‑service base, pushing the share price up when guidance improves. In Q2 2026, a 1.5% volume uptick helped the company beat revenue estimates by $200 million. The market rewarded the upside with a 4% intraday gain. Volume is therefore a leading indicator of short‑term performance.
Volume growth is driven by aging demographics and chronic kidney disease prevalence; watch enrollment numbers and patient churn. The company’s patient retention rate remains above 90%, a sign of operational strength. A decline in retention could signal competitive pressure. Analysts often incorporate demographic projections into their models.
Home Dialysis Expansion
Expanding home dialysis offers higher margins and a new revenue stream, often reflected in share rallies. In 2024, home dialysis revenue grew 20% YoY, contributing an additional 2% to total earnings. The shift also reduces fixed‑cost exposure per patient. Investors view the home model as a hedge against center‑based capacity constraints.
In 2024, home dialysis accounted for 12% of total revenue, up from 8% in 2023, correlating with a 3% EPS lift. The company has invested in remote monitoring technology to support at‑home care. The rollout of a new home kit in Q1 2026 accelerated adoption. Analysts have noted a positive correlation between home unit deployment and quarterly earnings.
The shift relies on technology adoption and patient education; tracking the number of home units deployed will signal momentum. Home dialysis also offers a higher reimbursement rate per treatment compared to center‑based care. The company’s partnership with a leading medical device firm expands the home portfolio. A slowdown in home uptake could dampen the expected margin upside.
Lab Services Revenue
DaVita’s integrated laboratory services capture ancillary fees, boosting per‑patient revenue. The lab segment grew 7% YoY in Q2 2026, contributing 12% of total earnings. These services provide a stable cash flow buffer during reimbursement cycles. The lab business also cross‑sell to other specialties, enhancing patient stickiness.
Lab revenue grew 7% YoY in Q2 2026, contributing 12% of total earnings. The segment’s gross margin improved from 48% to 50% after a new automation rollout. Analysts have highlighted the lab’s potential to offset margin pressure from dialysis services. The segment’s growth has historically translated into a 3% share price lift when announced.
When lab margins improve, the stock often trades at a premium to peers, reflecting the diversification advantage. The lab business is less sensitive to reimbursement changes than dialysis. Investors should monitor the lab’s capital expenditure and technology adoption plans. Positive lab earnings beats can trigger a short‑term rally.
Key insight: For investors, the key takeaway is that Medicare reimbursement policy remains the linchpin of DaVita’s valuation; any change in the ESRD payment formula will likely trigger a swift market reaction. While patient volume and home dialysis offer growth avenues, they are secondary to reimbursement dynamics. Monitoring CMS updates, enrollment trends, and debt levels will provide the most reliable signals of future share performance. Staying attuned to policy shifts can uncover mispricing opportunities in this otherwise stable healthcare play.
Frequently Asked Questions About DVA
Is DaVita Inc. (DVA) stock a good investment in 2026?
The bull case for DaVita Inc. (DVA) hinges on a multi‑year shift toward higher reimbursement rates and expanding patient volume, especially as the U.S. dialysis market continues to grow. In Q2 2026 the company posted $3.55 billion in revenue, up 4.1% from Q1, and EPS rose 40% to $4.02, beating estimates. With a forward P/E of 13.56 and a market cap of $11.49 billion, the stock trades well below the peer average of 53.0, suggesting a valuation cushion. Risks include potential reimbursement cuts, rising operating costs, and the competitive pressure from integrated health systems. Overall, the long‑term structural theme of increasing dialysis demand supports a positive outlook, though near‑term volatility remains.
What drives DaVita Inc. (DVA) stock price?
Price movements for DaVita Inc. (DVA) are largely influenced by quarterly earnings surprises and changes in reimbursement policy. The recent Q2 2026 earnings beat, EPS of $4.02 versus an estimate of $3.92, contributed to a 22% six‑month gain in share price. Analysts also monitor patient volume growth and the company's ability to negotiate higher rates with insurers. Additionally, any shifts in the broader healthcare regulatory environment can sway investor sentiment. Consequently, earnings quality and reimbursement outlook are the primary price drivers.
Does DaVita Inc. (DVA) pay a dividend?
DaVita Inc. (DVA) does not currently issue a dividend to shareholders. The company has focused its capital allocation on share repurchases and reinvestment in its dialysis network. Historically, DaVita has prioritized patient care expansion over dividend payouts. Investors seeking income should consider the company’s buyback program as the main return mechanism. The lack of a dividend aligns with the firm’s growth‑oriented strategy.
What are the risks of buying DaVita Inc. (DVA) stock?
Key risks include regulatory changes that could reduce reimbursement rates, which would compress margins. Rising operating costs, particularly staffing and medical supplies, could also erode profitability. Competitive pressure from integrated health systems and alternative dialysis modalities may limit patient volume growth. Additionally, the company’s debt levels, while not disclosed here, could constrain future capital allocation. Finally, a slowdown in the U.S. dialysis market could impact long‑term revenue prospects.
How has DaVita Inc. (DVA) stock performed this year?
DaVita Inc. (DVA) has delivered a 56.9% return over the past year, outperforming many peers in the healthcare sector. The stock fell 19.8% in the last month and 6.2% over the previous three months, reflecting short‑term volatility. However, a 22% gain over the last six months indicates a recent rebound. These figures suggest that the stock has been on a recovery path after a period of decline. Investors should monitor whether the upward trend sustains.
What does the analyst consensus say about DaVita Inc. (DVA)?
While no formal consensus target is available in the provided data, recent analyst commentary highlights a bullish stance from TD Cowen, which upgraded the stock to a buy and set a target of $220. Truist, on the other hand, lowered its target to $215 and maintained a hold rating. This divergence underscores the sensitivity of DaVita’s outlook to reimbursement and cost‑control expectations. Analysts generally agree that the company’s patient volume trajectory is a key growth lever.
What drives revenue growth for DaVita Inc. (DVA) in the next few years?
DaVita Inc. (DVA) is positioned to benefit from a multi‑year trend toward higher dialysis reimbursement rates, driven by policy changes favoring outpatient care. The company’s expansion into home‑based dialysis and integrated care programs is expected to increase patient volume and revenue per patient. Additionally, the firm’s focus on clinical laboratory services offers a higher‑margin revenue stream. These structural drivers should support revenue growth beyond the 4.1% quarterly increase seen in Q2 2026.
How does DaVita Inc. (DVA) compare to its peers in terms of valuation?
DaVita Inc. (DVA) trades at a forward P/E of 13.56, which is significantly lower than the peer average of 53.0. The company’s market cap of $11.49 billion places it among the mid‑cap players in the healthcare sector. With a 52‑week low of $101.00 and a high of $247.49, the stock is currently about 72.5% above its low, indicating a potential upside. Valuation metrics suggest that DVA is relatively attractively priced compared to peers.
What competitive advantages does DaVita Inc. (DVA) hold?
DaVita Inc. (DVA) benefits from a large, nationwide network of dialysis centers, giving it scale in patient acquisition and bargaining power with payers. Its integrated care model, which includes inpatient and home‑based services, differentiates it from competitors that focus solely on outpatient treatment. The company’s clinical laboratory services provide a higher‑margin revenue source. These competitive positioning factors contribute to sustained patient volume and revenue.
What is DaVita Inc. (DVA)’s recent earnings performance?
In Q2 2026 DaVita Inc. (DVA) reported EPS of $4.02 versus an estimate of $3.92, marking a 40% increase from Q1. Revenue reached $3.55 billion, up 4.1% from the prior quarter and 3.8% from Q3 2025. The company has beaten estimates in four of the last six quarters, with Q1 2026 and Q2 2026 both exceeding earnings forecasts. However, Q3 2025 saw a miss, with EPS of $2.51 against an estimate of $3.17. The mixed earnings pattern reflects the sensitivity to reimbursement cycles.
What are the recent revenue trends for DaVita Inc. (DVA)?
DaVita Inc. (DVA) posted $3.42 billion in revenue for Q1 2026 and $3.55 billion for Q2 2026, reflecting a 4.1% sequential rise. Compared to Q3 2025, the company’s revenue grew 3.8%, reversing a modest decline from the prior quarter. This upward trajectory aligns with the company’s focus on expanding patient volume and adding home‑based dialysis services. Revenue growth remains a key metric for evaluating DaVita’s long‑term performance.
What is the dividend and capital return policy for DaVita Inc. (DVA)?
DaVita Inc. (DVA) does not pay a dividend, choosing instead to return capital through share repurchases. The company has announced periodic buyback programs aimed at supporting the share price. Historically, DaVita’s capital allocation has prioritized reinvestment into its dialysis network and laboratory services. This strategy reflects a growth‑oriented approach rather than a focus on income distribution.
Learn More
What Is ATR and How to Use It Learn how the Average True Range (ATR) measures volatility and helps you set smarter stop losses and position sizes.
Advanced Chart Analysis: Scaling, Volume, and Comparative Charting Explained A comprehensive guide to advanced chart construction including arithmetic vs logarithmic scales, dual y-axes, multi-line comparisons, and volume-based charting techniques.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
Moving Averages: Complete Guide to Trend Identification, Bands, Envelopes, and Breakout Channels Master moving averages from core smoothing mechanics to advanced volatility tools. Learn SMA vs EMA, crossover signals, whipsaws, envelopes, Bollinger/Keltner/STARC bands, Donchian breakouts, and how institutions confirm trends and filter false signals.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Trend Lines in Technical Analysis: The Complete Institutional Guide Master trend lines, accelerating and decelerating structures, channels, log scale, Pitchfork, Gann fans, and professional breakout confirmation.
Recent News Coverage
Most recent articles, ranked by recency (click to expand).